HER2 expression status in diverse cancers: review of results from 37,992 patients
Abstract Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been reported in other malignancies, previous studies generally focused on one cancer type, making it challenging to compare HER2 positivity across studies/malignancies. Herein, we examined 37,992 patient samples for HER2 expression (+/− amplification) in a single laboratory. All 37,992 patients were tested by immunohistochemistry (IHC); 21,642 of them were also examined for HER2 amplification with either fluorescent in situ hybridization (FISH) (11,670 patients) or chromogenic in situ hybridization (CISH) (9,972 patients); 18,262 patients had tumors other than breast or gastric cancer. All tissues were analyzed in a Clinical Laboratory Improvement Amendments (CLIA) laboratory (Caris Life Sciences) at the request of referring physicians. HER2 protein overexpression was found in 2.7 % of samples. Over-expressed HER2 was detected predominantly in malignancies of epithelial origin; for cancers derived from mesenchyme, neuroendocrine tissue, central nervous system, and kidney, HER2 expression and amplification were remarkably rare or non-existent. Bladder carcinomas, gallbladder, extrahepatic cholangiocarcinomas, cervical, uterine, and testicular cancers showed HER2 positivity rates of 12.4, 9.8, 6.3, 3.9, 3.0, and 2.4 %, respectively. HER2 overexpression and/or amplification is...
Authors: DiCaprio MR, Abousayed MM, Kambam MLR Abstract Melanoma is an aggressive form of skin cancer associated with significant morbidity and mortality. Although commonly seen in dermatologist clinics, orthopaedic surgeons must be aware of these lesions in various ways. The five common musculoskeletal manifestations of melanoma will be discussed as well as the epidemiology, pathogenesis, diagnosis, staging, treatment, and prognosis of melanoma. With an index of suspicion and awareness of melanoma, a thorough history and detailed physical examination are critical in establishing a diagnosis. An adequately performe...
Publication date: Available online 25 February 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Milan Vošmik, Miroslav Hodek, David Buka, Petra Sýkorová, Jakub Grepl, Petr Paluska, Simona Paulíková, Igor Sirák
Publication date: Available online 26 February 2020Source: Practical Radiation OncologyAuthor(s): Kimberly R. Gergelis, Cole R. Kreofsky, Christopher S. Choo, Jason Viehman, W Scott Harmsen, Scott C. Lester, Thomas M. Pisansky, Brian J. Davis, Bradley J. Stish, Richard Choo
Publication date: April 2020Source: Cancer Genetics, Volume 242Author(s):
Publication date: Available online 26 February 2020Source: Cancer GeneticsAuthor(s): Stewart G. Neill, Jennifer Hauenstein, Marilyn M. Li, Yajuan J Liu, Minjie Luo, Debra F. Saxe, Azra H. Ligon
Date: Friday, 02 28, 2020; Speaker: Dr. Weiping Zou, Professor of Pathology, Immunology, Biology&Surgery, University of Michigan School of Medicine; Building: NCI at Frederick, Building 549
CONCLUSION: Ultrasound and MRI have similar diagnostic performance for detecting parametrial infiltration in women with cervical cancer. This might have relevance from the clinical point of view, since ultrasound is cheaper than MRI. PMID: 32096793 [PubMed - as supplied by publisher]
CONCLUSION: By using the combination of ultrasound modes, this approach achieves high performance compared with the single mode and other fusion strategies. Our methodology may be a beneficial tool for the early detection and diagnosis of breast cancer. PMID: 32096788 [PubMed - as supplied by publisher]
CONCLUSIONS: In cases of BCCs with thickness of ≤1 mm, there was a high correlation (r=0.870) of the tumor spread depth between micromorphological measurements and the results obtained using a 75 MHz transducer and in cases of BCCs with thickness of>1 mm, a very high correlation (r=0.951) of the tumor spread depth was observed between histomorphometry and30 MHz transducer measurements. PMID: 32096785 [PubMed - as supplied by publisher]
CONCLUSIONS: EUS guided fine needle aspiration/biopsy of focal liver lesions is safe, provides a very high diagnostic accuracy and should not be considered only as a rescue method after failure of percutaneous guided biopsies. PMID: 32096783 [PubMed - as supplied by publisher]
More News: Bile Duct Cancer | Bladder Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Cervical Cancer | Cholangiocarcinoma | Epithelial Cancer | Gallbladder Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Laboratory Medicine | Neurology | Study | Testicular Cancer | Urology & Nephrology